Did expired antivirals kill Nipah patients in Kerala? Govt's claim, Left's counter

The Kerala government is investigating Nipah treatment at Government Medical College Kozhikode during 2023, 2024 and 2025. Health minister K. Muraleedharan ordered a high-level inquiry after claiming that expired Remdesivir may have been administered to patients. A medical board will scrutinise the treatment protocol followed.

The investigation will examine stock records, usage data and patient treatment details. The government says 3,000 Remdesivir vials were bought in June 2021, with expiry set for May 30, 2023. It says 102 expired vials were used in 2023-24, 34 in 2024-25 and 10 in 2025-26.

The issue matters because six Nipah patients died during the period under review. Former health minister Veena George and treating doctors dispute the government’s interpretation. They say the six patients who died did not receive Remdesivir, while seven patients who received it recovered. The medical board is expected to test these competing claims.

Remdesivir is an antiviral drug. Antivirals are medicines designed to interfere with a virus’s ability to multiply or spread inside the body. Doctors may consider one when a patient has a serious viral infection and the potential benefits outweigh the risks. The article identifies Remdesivir as the antiviral given to some Nipah patients at Kozhikode.

Nipah treatment can involve urgent decisions because patients may become critically ill. Veena George said an expert panel and medical board were formed before Nipah antivirals were administered. Dr A.S. Anoop Kumar said seven patients who received Remdesivir recovered, while six others were too seriously ill to receive it.

That contrast does not, by itself, prove that Remdesivir caused recovery. The article gives no controlled comparison or confirmed finding about the drug’s effectiveness against Nipah. The government’s inquiry will examine treatment records and protocols before drawing conclusions about its use or safety.

The government says 146 Remdesivir vials were used after their stated expiry date. Its breakdown is 102 vials in 2023-24, 34 in 2024-25 and 10 in 2025-26. The original stock consisted of 3,000 vials bought for Rs 42 lakh in June 2021, each carrying a May 30, 2023 expiry date.

The figures come from stock and usage data records cited by health minister K. Muraleedharan. The government linked the records to Nipah treatment at Kozhikode Government Medical College. It also said six people died during the outbreaks and treatment period being examined, although the article does not say all six received the expired medicine.

That distinction is central to the dispute. Former health minister Veena George said none of the patients who died received Remdesivir. Dr A.S. Anoop Kumar gave the same account, saying seven patients who received it recovered. The inquiry is intended to verify the records and treatment details.

Health minister K. Muraleedharan said the government suspected Kozhikode Medical College had administered expired Remdesivir to Nipah patients. He cited records showing expired vials were used between 2023 and 2025 and mentioned six deaths. His statement prompted the government’s inquiry, but the article does not quote him explicitly saying all six deceased patients received the drug.

Veena George, who was health minister during the LDF government, directly rejected that interpretation. She said none of the patients who received Remdesivir died at Kozhikode Medical College during 2023-25. She also said treatment details were recorded and available for scrutiny.

Dr A.S. Anoop Kumar supported George’s account. He said the six patients who died were admitted in serious condition and could not be given the antiviral. He said seven patients who received Remdesivir recovered. These conflicting accounts make the medical records and inquiry especially important.

Using an expired medicine is concerning because its quality, strength or stability may no longer be assured after the labelled date. That can make treatment less predictable, especially for critically ill patients. It can also indicate problems with stock control or treatment oversight. The Kerala government therefore ordered an inquiry into the reported use of expired Remdesivir.

However, an expiry date does not automatically establish that a patient was harmed. Investigators must first confirm that the patient actually received the medicine, identify the dose and timing, and check whether the drug remained usable. They must also consider the patient’s condition, Nipah severity and other treatments.

That is why the dispute cannot be settled by vial counts alone. Veena George and Dr A.S. Anoop Kumar say the six patients who died never received Remdesivir. They say seven recipients recovered. Medical records, expert review and the treatment timeline are needed to assess any causal connection.

Nipah virus is a zoonotic virus that can pass from animals to people and, in some situations, between people. It can cause severe illness, including inflammation of the brain, breathing problems and multi-organ complications. This makes rapid diagnosis, intensive care and infection control important. These medical details come from established medical knowledge; the article mainly focuses on treatment disputes.

Kerala reported Nipah outbreaks in 2018, 2019, 2021, 2023, 2024 and 2025. The article says 22 lives have been lost across those outbreaks. It also reports one confirmed Nipah case in June of the current year and says the UDF government procured 50 Remdesivir vials from Bahrain on June 12.

The repeated outbreaks explain why treatment protocols matter politically and medically. The previous LDF government had received praise for managing Nipah infections. The latest dispute over expired medicine has led to a formal inquiry and renewed scrutiny of public hospital practices.

Medical investigations begin by establishing what happened to each patient. Doctors review diagnosis, illness severity, test results, medicine name, dose, timing and other care. Treatment records and pharmacy logs can show whether a patient actually received a drug. A medical board then compares those details with the patient’s recovery or death.

In this case, the article says an expert panel and medical board were formed before Nipah antivirals were administered. The inquiry can compare the six deaths with the seven recoveries reported by Dr A.S. Anoop Kumar. It can also check the government’s stock records against individual patient files.

The key mechanism is causal assessment, not simple association. Recovery after Remdesivir does not prove the drug caused recovery, just as death during a treatment period does not prove the drug caused death. Investigators must consider disease severity, timing and alternative explanations before reaching a conclusion.